Radsource Completes 15 ProtonPACS Installations in the Fourth Quarter of 2021
Share Article
Radsource, a leader in radiology clinical services and provider of Picture Archiving and Communication Systems (PACS), completed 15 installations of ProtonPACS in the second quarter of 2021.
“Every time we have a question, the implementations team has quickly provided an answer and then helped us create a smooth and efficient workflow. Overall, working with Radsource has been a winning experience with a fantastic team.” NASHVILLE, Tenn. (PRWEB) July 21, 2021 Radsource, a leader in radiology clinical services and provider of Picture Archiving and Communication Systems (PACS), completed 15 installations of ProtonPACS in the second quarter of 2021.
How Oncology Practices Weathered the Pandemic Storm medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recu